Acta Scientific Pharmacology

Short Communication Volume 3 Issue 3

Factual Basis of Conventional Therapies in Metastatic Cancer Treatment - An Overview

K Ramalingam1* and P Karnan2

1Mediclone Biotech Research Centre, Chennai-48, Dr. Rai Memorial, Medical Centre (Cancer Treatment and Research), I.E.C Member, India
2Associate Professor, GRT College of Education, Tiruttani, India

*Corresponding Author: K Ramalingam, Mediclone Biotech Research Centre, Chennai-48, Dr. Rai Memorial, Medical Centre (Cancer Treatment and Research), I.E.C Member, India.

Received: January 01, 2022 Published: February 16, 2022

Abstract

Cancer research towards the goal of Ehrlich’s magic bullets has become an all time exciting and salubrious subject due to novel mechanisms involved in cancer cells which tilt the balance towards their success of survival and failure of novel drugs in the armamentaria of chemotherapy. Still the disease cancer remains as untreatable one beyond the metastatic stage. Both conventional and non conventional bio therapies became in vain futile attempts in rescuing a metastatic cancer patients who is defenseless with poor immune potential and weak and fragile to tolerate further the impacts of cyto-toxic chemotherapy and its side-effects. A meta-analysis of both conventional and non conventional therapies could bring new insights in the research of oncology towards the accomplishment of real-magic bullets. The subtle question that remains is why chemotherapy and radiation fail and why phytotherapy was unrecognized for cancer treatment by FDA USA. This is the utmost important goal in view of the fact (WHO) that almost 50 percent of global population will suffer from cancer disease in the near future.

Keywords: Chemotheraphy; Monoclonal Abs; Interleukines; Neuropeptides; Magic Bullets; Phytochemicals

References

  1. De Vita V., et al. “Cancer: Principles and practice of oncology”. Lippincott. Philadelphia USA (1993).
  2. Ramalingam K. “The Prudent Proxiex to Prevent Cancer-II Personal Publication, Chennai” (2018).
  3. Ramalingam K. “The Prudent Proxies to prevent cancer I Personal Publication, Chennai” (2015).
  4. Kohler G and Milstein C. “Continuous cultures of fused cells secreting antibody of predefined specificity”. Nature 256 (1975): 495-497.
  5. Epenetos AA., et al. “Limitations of radio-Rebelled monoclonal antibodies for localization of Human neo plasoms”. Cancer Research 46 (1986): 3183-3191.
  6. Petrov RV., et al. “Control and Reguelation of the immune response”. Meditsina, Leningrad (in Russian) (1981).
  7. K Ramalingam and UD Bharathi Rajan. “An analysis of the current knowledge about crustacean immunity and diseases with an overview of vertebrate system”. Uttar Pradesh Journal of Zoology 2 (2007): 135-158.
  8. Barsky SH., et al. “Laminin molecular domains which alter metastasis murine modal”. Journal of Clinical Investigation 74 (1984): 843-884.
  9. Eisen HN., et al. “A myolema protein with antibody activity”. Cold Spring Harbor Symposia on Quantitative Biology 32 (1967): 75-97.
  10. Port CB., et al. “Octapeptides deduced from the neuropeptide receptor like pattern of antigen T4 in brain potently inhibit Human imuno deficiency virus. Receptor binding and T-cell infectivity”. Proceedings of the National Academy of Sciences of the United States of America 83 (1985): 9254-9258.

Citation

Citation: K Ramalingam and P Karnan. “Factual Basis of Conventional Therapies in Metastatic Cancer Treatment - An Overview". Acta Scientific Pharmacology 3.3 (2022): 05-07.

Copyright

Copyright: © 2022 K Ramalingam and P Karnan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate36%
Acceptance to publication20-30 days

Indexed In


News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US